Business and Finance

In a move meant to encourage domestic production, the president’s executive order features a 10% baseline tax, expected to take effect April 9.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a month, while Lilly also sells the GLP-1 via its LillyDirect platform.

CRYOPDP—centered around clinical trials, biopharma, and cell and gene therapies—augments DHL’s specialty pharma logistics expertise.

The move by the CDMO—who also houses a North American HQ in Indiana—expresses its interest in providing compliant storage and logistics solutions globally.

The Beijing location represents the sixth worldwide.

What drivers impact the differences in expenditures?

Why having these strategies for results—amid disruptions—will be critical to success.

The thermal packaging company not only bolsters its APAC presence—it also grows its influence in the life sciences’ temperature-monitoring logistics sector.

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

The updated tax on Canadian imports will rise from 25% to 50%, taking effect March 12.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.

The US president delays tariffs that comply with the 2020 USMCA for one month, with reciprocal tariffs still expected to go into effect by April 2.

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering access to academic and startup communities.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations.

After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.

The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.

The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring.

A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.

The company’s Mourenx plant in Southwest France aims to become an API network hub, with first supplies expected by next year.

These taxes on goods—with the potential to take effect in weeks or months—will vary by country, but rates could depend on regulations, industry subsidies, and other factors.

The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.

Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific regulatory updates that drug developers be closely monitoring in the current landscape.

The agreement is centered around improving cell culture efficiency and CGT quality.

A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency.

What factors should be considered—and how can both parties benefit long-term?